- Description
- Product Info
- Shipping and Storage
- Downloads
- References
Description
This compound is a cysteine-isothiocyanate conjugate that exhibits antioxidative, cytoprotective, nephroprotective, and chemopreventive activities. In vivo, this compound decreases lung tumor formation induced by benzo[a]pyrene and NNK. Additionally, this isothiocyanate (ITC) increases expression and activity of heme oxygenase 1 (HO-1) and decreases renal tissue apoptosis induced by cisplatin. Like other ITCs, this compound also acts as a phase II enzyme inducer.
Product Info
137915-13-0 |
≥98% |
C13H18N2O2S2 |
298.42 |
(2R)-2-amino-3-(3-phenylpropylcarbamothioylsulfanyl)propanoic acid |
S-(N-(3-Phenylpropyl)(thiocarbamoyl))-cysteine |
202-205°C |
White solid |
Shipping and Storage
-20°C |
Ambient |
Downloads
P2816 Info Sheet PDF |
References
Tayem Y, Green CJ, Motterlini R, et al. Isothiocyanate-cysteine conjugates protect renal tissue against cisplatin-induced apoptosis via induction of heme oxygenase-1. Pharmacol Res. 2014 Mar;81:1-9. PMID: 24434421.
Hecht SS, Upadhyaya P, Wang M, et al. Inhibition of lung tumorigenesis in A/J mice by N-acetyl-S-(N-2-phenethylthiocarbamoyl)-L-cysteine and myo-inositol, individually and in combination. Carcinogenesis. 2002 Sep;23(9):1455-61. PMID: 12189187.
